Essentials of Atrial Fibrillation e-bog
546,06 DKK
(ekskl. moms 436,85 DKK)
This handbook offers timely investigation of current pharmaceutical trends, clinical guidelines, novel treatments, and ongoing pipeline developments, including ground-breaking advances in the use of novel oral anticoagulants. Atrial fibrillation (AF) affects an estimated 1-2% of the population and is the most common cause of sustained cardiac arrhythmia. Critically, the number of patients develop…
This handbook offers timely investigation of current pharmaceutical trends, clinical guidelines, novel treatments, and ongoing pipeline developments, including ground-breaking advances in the use of novel oral anticoagulants. Atrial fibrillation (AF) affects an estimated 1-2% of the population and is the most common cause of sustained cardiac arrhythmia. Critically, the number of patients developing AF is expected to double in the next five decades, leading to increased incidence of stroke, heart failure and other serious thromboembolic events.
E-bog
546,06 DKK
Forlag
Springer Healthcare
Udgivet
25.09.2014
Genrer
Public health and preventive medicine
Sprog
English
Format
pdf
Beskyttelse
LCP
ISBN
9781907673986
This handbook offers timely investigation of current pharmaceutical trends, clinical guidelines, novel treatments, and ongoing pipeline developments, including ground-breaking advances in the use of novel oral anticoagulants. Atrial fibrillation (AF) affects an estimated 1-2% of the population and is the most common cause of sustained cardiac arrhythmia. Critically, the number of patients developing AF is expected to double in the next five decades, leading to increased incidence of stroke, heart failure and other serious thromboembolic events.
Dansk